These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy. Vaishnav J; Brown E; Sharma K Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305 [TBL] [Abstract][Full Text] [Related]
26. Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis. Gawor M; Holcman K; Franaszczyk M; Lipowska M; Michałek P; Teresińska A; Bilińska ZT; Rubiś P; Kostkiewicz M; Szot W; Podolec P; Grzybowski J Cardiol J; 2022; 29(6):985-993. PubMed ID: 32789836 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis of genetic amyloidosis through the analysis of transthyretin gene mutation using high-resolution melting. Lahuerta C; Menao S; Gracia-Gutierrez A; Bueno-Juana E; Guillén N; Sorribas V; Gracia AA; Aibar MA Int J Cardiol; 2020 Feb; 301():220-225. PubMed ID: 31740141 [TBL] [Abstract][Full Text] [Related]
28. Amyloid Cardiomyopathy. Bart NK; Thomas L; Korczyk D; Atherton JJ; Stewart GJ; Fatkin D Heart Lung Circ; 2020 Apr; 29(4):575-583. PubMed ID: 32001152 [TBL] [Abstract][Full Text] [Related]
29. A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report. Thimm A; Oubari S; Hoffmann J; Carpinteiro A; Papathanasiou M; Luedike P; Kessler L; Rischpler C; Röcken C; Diebold I; Rassaf T; Schmidt H; Kleinschnitz C; Hagenacker T BMC Neurol; 2022 Dec; 22(1):469. PubMed ID: 36494773 [TBL] [Abstract][Full Text] [Related]
30. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867 [TBL] [Abstract][Full Text] [Related]
31. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
32. [Neurological manifestations of ATTR amyloidosis]. Pernice HF; Hahn K Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967 [TBL] [Abstract][Full Text] [Related]
33. Amyloid cardiomyopathy. Kristen AV Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564 [TBL] [Abstract][Full Text] [Related]
34. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383 [TBL] [Abstract][Full Text] [Related]
35. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244 [TBL] [Abstract][Full Text] [Related]
36. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment. Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ Curr Heart Fail Rep; 2024 Aug; 21(4):344-353. PubMed ID: 38775878 [TBL] [Abstract][Full Text] [Related]